1 completed, 1 terminated. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow InCarda Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation FlecIH-103 - Paroxysmal Atrial Fibrillation | Phase 3 | Terminated | InCarda Therapeutics, Inc. | 54 | 2022-04-26 | 2023-10-30 |
| INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT) Flecainide Acetate - Paroxysmal Atrial Fibrillation (PAF) | Phase 2 | Completed | InCarda Therapeutics, Inc. | 176 | 2018-05-29 | 2024-05-14 |
Flecainide (1)
Netherlands (2) · Belgium (1) · Czechia (1) · Hungary (1) · Poland (1) · Spain (1) · United States (1)